Brand Name | Status | Last Update |
---|---|---|
elitek | Biologic Licensing Application | 2024-10-04 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hyperuricemia | — | D033461 | — |
tumor lysis syndrome | — | D015275 | E88.3 |
Expiration | Code | ||
---|---|---|---|
rasburicase, Elitek, Sanofi-Aventis U.S. LLC | |||
2109-07-12 | Orphan excl. |
Code | Description |
---|---|
J2783 | Injection, rasburicase, 0.5 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | 1 | — | — | — | 1 |
Nutritional and metabolic diseases | D009750 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Rasburicase |
INN | rasburicase |
Description | Uricase (Urate oxidase) |
Classification | Enzyme |
Drug class | enzymes |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201594 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00049 |
UNII ID | 08GY9K1EUO (ChemIDplus, GSRS) |